Hunajaa ja pölytyspalveluja : laadukasta liiketoimintaa mehiläistarhauksesta

Laadukasta liiketoimintaa luonnosta -hanke toteutettiin vuosina 2011–2015, ja sitä hallinnoi Helsingin yliopiston Ruralia-instituutin Mikkelin yksikkö. Hanketta osarahoitti Etelä-Savon ELY-keskus Euroopan unionin Euroopan sosiaalirahastosta. Hanke koostui kolmesta osasta, jotka olivat 1. Mehiläistarhaajien koulutus, 2. Luonto- ja elintarvikealan yritysten koulutus sekä 3. Maatilan ympäristönhoito ja luonnonsuojelu. Hankkeen kohderyhminä olivat eteläsavolaiset mehiläistarhaajat, luonnontuote- ja elintarvikealan yrittäjät tai sellaisiksi aikovat sekä maatilojen ympäristönhoidon osaamisen syventämisestä kiinnostuneet. Hanke vastasi kentältä tulleisiin tarpeisiin, joita oli kartoitettu ennen hankkeen suunnittelua hankkeen kohderyhmiltä kyselyillä ja yhteenvedoilla saaduista koulutustoiveista. Koulutusten teoriaosuudet toteutettiin pääosin Mikkelissä, Helsingin yliopiston Ruralia-instituutissa. Eri koulutuksiin sisältyi myös etäopiskelua ja yrityskohtaista neuvontaa. Jokaisesta hankkeen kolmesta osiosta laadittiin Ruralia-instituutin Julkaisuja-sarjaan raportti, johon poimittiin hankkeen parhaita käytäntöjä ja kiinnostavimpia tapahtumia ja tuloksia. Tämä raportti kertoo hankkeen mehiläiskoulutusosiosta, joka toteutettiin pääosin vuosina 2011–2012. Koulutus koostui kahdeksasta 2–3 päivän lähiopetusjaksosta, käytännön harjoittelusta ammattimehiläistarhoilla ja opintomatkasta Itävaltaan ja Sloveniaan. Koulutukseen kuului lisäksi verkkoavusteista etäopiskelua sekä portfolion ja oman toimintasuunnitelmana laatiminen. Hankkeessa järjestettiin lisäksi vuonna 2014 viiden päivän täydennyskoulutus sekä kaikille hankkeen kohderyhmille suunnattuja yhteisiä tilaisuuksia. Näistä tilaisuuksista on raportoitu hankkeen luonnontuote- ja elintarvikeosion raportissa. Mehiläiskoulutuksen tuloksena osallistujat saivat valmiudet ammatti- tai sivutoimiseen tarhaukseen ja pesien lukumäärä kasvoi liki sadalla pesällä

Modelling and Simulation of Radial Spruce Compression to Optimize Energy Efficiency in Mechanical Pulping

acceptedVersionPeer reviewe

Influence of strain rate, temperature and fatigue on the radial compression behaviour of Norway spruce

A dynamic elastoplastic compression model of Norway spruce for virtual computer optimization of mechanical pulping processes was developed. The empirical wood behaviour was fitted to a Voigt-Kelvin material model, which is based on quasi static compression and high strain rate compression tests (QSCT and HSRT, respectively) of wood at room temperature and at high temperature (80-100°C). The effect of wood fatigue was also included in the model. Wood compression stress-strain curves have an initial linear elastic region, a plateau region and a densification region. The latter was not reached in the HSRT. Earlywood (EW) and latewood (LW) contributions were considered separately. In the radial direction, the wood structure is layered and can well be modelled by serially loaded layers. The EW model was a two part linear model and the LW was modelled by a linear model, both with a strain rate dependent term. The model corresponds well to the measured values and this is the first compression model for EW and LW that is based on experiments under conditions close to those used in mechanical pulping.publishedVersionPeer reviewe

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Ibrutinib, a Brutons tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and routine healthcare are commonly observed in oncology. Herein we report real-world results for 95 poor prognosis Swedish patients treated with ibrutinib in a compassionate use program. Ninety-five consecutive patients (93 chronic lymphocytic leukemia, 2 small lymphocytic leukemia) were included in the study between May 2014 and May 2015. The median age was 69 years. 63% had del(17p)/TP53 mutation, 65% had Rai stage III/IV, 28% had lymphadenopathy amp;gt;= 10cm. Patients received ibrutinib 420 mg once daily until progression. At a median follow-up of 10.2 months, the overall response rate was 84% (consistent among subgroups) and 77% remained progression-free. Progression-free survival and overall survival were significantly shorter in patients with del(17p)/TP53 mutation (P=0.017 and P=0.027, log-rank test); no other factor was significant in Cox proportional regression hazards model. Ibrutinib was well tolerated. Hematomas occurred in 46% of patients without any major bleeding. Seven patients had Richters transformation. This real-world analysis on consecutive chronic lymphocytic leukemia patients from a well-defined geographical region shows the efficacy and safety of ibrutinib to be similar to that of pivotal trials. Yet, del(17p)/TP53 mutation remains a therapeutic challenge. Since not more than half of our patients would have qualified for the pivotal ibrutinib trial (RESONATE), our study emphasizes that real-world results should be carefully considered in future with regards to new agents and new indications in chronic lymphocytic leukemia.Funding Agencies|Swedish Cancer Society [15 0894]; Cancer Society in Stockholm [144142, 151313]; King Gustav V Jubilee Fund [144193]; Cancer and Allergy Foundation [150 420, 150 431]; StratCan Karolinska Institutet [2201]; AFA Insurance [130054]; Stockholm County Council, Sweden [20150070]</p

Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia : A Swedish nation-wide real-world report on consecutively identified patients

Objectives We examined the efficacy and toxicity of the PI3Kδ inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL). Methods and Results Thirty-seven patients with relapsed/refractory disease were included. The median number of prior lines of therapy was 3 (range 1–11); the median age was 69 years (range 50–89); 22% had Cumulative Illness Rating Scale (CIRS) &gt;6 and 51% had del(17p)/TP53 mutation. The overall response rate was 65% (all but one was partial response [PR]). The median duration of therapy was 9.8 months (range 0.9–44.8). The median progression-free survival was 16.4 months (95% CI: 10.4–26.3) and median overall survival had not been reached (75% remained alive at 24 months of follow-up). The most common reason for cessation of therapy was colitis (n = 8, of which seven patients experienced grade ≥3 colitis). The most common serious adverse event was grade ≥3 infection, which occurred in 24 patients (65%). Conclusions Our real-world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced-stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double-refractory to inhibitors of BTK and Bcl-2

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia : 30-month follow up of the Swedish compassionate use cohort

n/

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

Purpose Despite therapeutic advances, patients with multiple myeloma (MM) continue to experience disease relapse and treatment resistance. The gene ABCB1 encodes the drug transporter P-glycoprotein, which confers resistance through drug extrusion across the cell membrane. Lenalidomide (Len) is excreted mainly via the kidneys, and, given the expression of P-gp in the renal tubuli, single-nucleotide polymorphisms (SNPs) in the ABCB1 gene may influence Len plasma concentrations and, subsequently, the outcome of treatment. We, therefore, investigated the influence of ABCB1 genetic variants on Len treatment outcomes and adverse events (AEs). Methods Ninety patients with relapsed or refractory MM, who received the second-line Len plus dexamethasone in the Rev II trial, were genotyped for the ABCB1 SNPs 1199G amp;gt; A (Ser400Asn, rs2229109), 1236C amp;gt; T (silent, rs1128503), 2677G amp;gt; T/A (Ala893Ser, rs2032582), and 3435C amp;gt; T (silent, rs1045642) using pyrosequencing, and correlations to response parameters, outcomes, and AEs were investigated. Results No significant associations were found between genotype and either best response rates or hematological AEs, and 1236C amp;gt; T, 2677G amp;gt; T or 3435C amp;gt; T genotypes had no impact on survival. There was a trend towards increased time to progression (TTP) in patients carrying the 1199A variant, and a significant difference in TTP between genotypes in patients with standard-risk cytogenetics. Conclusions Our findings show a limited influence of ABCB1 genotype on lenalidomide treatment efficacy and safety. The results suggest that 1199G amp;gt; A may be a marker of TTP following Len treatment in standard-risk patients; however, larger studies are needed to validate and clarify the relationship.Funding Agencies|Swedish Cancer Society; Swedish Research Council; AFA Insurance; Linkoping University; ALF Grants, Region Ostergotland; Celgene Corporation</p